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A bite from a tiny sand fly can be nearly impercepti-ble. But the aftermath can be devastating. Sand flies are the vectors for leishmaniasis, a parasitic disease that affects 12 million people 
in the tropics, as well as dogs and other mammals. The 
cutaneous form of the disease causes unsightly skin ulcers 
that take months or even years to heal, and can progress to 
cause severe, disfiguring tissue damage.
“This is classically what you would call a ‘developing-
world disease,’ since it gets little attention,” says Dr. Phillip 
Scott, Vice Dean for Research and Academic Resources and 
Professor of Immunology at Penn Vet. “There is no vaccine 
and the drugs that are currently used to treat this disease are 
not very effective and can be quite toxic.”
For more than three decades, Scott has been partnering 
with scientists in Brazil and across Penn to better understand 
the underlying biology of the disease, with a goal of 
identifying treatments that are both safe and effective. They 
are already moving from laboratory bench to bedside, with 
plans for a clinical trial.
Leishmaniasis is a particularly insidious disease because the 
parasite lives and replicates inside the very cells that would 
normally kill it: macrophages. After a bite from an infected 
sand fly, the parasite enters the skin; macrophages engulf the 
parasite and recruit T cells to help vanquish the infection. T 
cells, in turn, produce interferon gamma (IFNγ), a signaling 
molecule that instructs macrophages to kill off the pathogen. 
Yet when researchers took tissue samples from people 
with leishmaniasis infections, they observed something 
puzzling. Some patients who had low levels of parasite and 
high levels of IFNγ, indicating that the immune system was 
strongly responding to the infection, still had extremely 
severe forms of the disease. This scenario of low parasite 
levels yet high IFNγ is particularly common in parts of 
Brazil, where Scott has worked in a clinic that sees about 
1,500 leishmaniasis patients each year.
“Whenever you have this spectrum of clinical 
presentation, you can’t help but wonder, ‘Why does that 
happen?’ In my lab, we’re looking for ways to modulate the 
immune response to help patients avoid the most horrific 
forms of this disease,” Scott says.
To investigate the reasons why some patients suffer such 
serious forms of leishmaniasis, Scott and colleagues have 
conducted studies in mice in his lab at Penn Vet, and in 
human patients at the Brazilian clinic—located in Corte de 
Pedra, about 3.5 hours from Brazil’s first capital, Salvador. 
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The work, which has been supported in large part by 
National Institutes of Health grants awarded to Scott, 
has pointed to an unexpected culprit in severe cutaneous 
disease: a type of T cell called CD8 cells. 
In some cases, these cells can help clear leishmania 
infection. But they also have a dark side. Working with 
postdoctoral researcher Fernanda Novais, a native Brazilian, 
Scott used a spinning disk confocal microscope to make 
videos of mouse T cells attacking the leishmania parasite. 
They saw that CD8 cells can actually lyse, or pop open, 
infected macrophages. Like poking at a hornet’s nest, the T 
cells end up exacerbating disease by releasing live parasites 
and inflammatory factors from macrophages, which can then 
diffuse into surrounding tissue, inflaming tissue and causing 
skin lesions to worsen.
With this new model of leishmaniasis pathology in hand, 
Scott’s lab and partners in Brazil have begun trying to 
understand the factors that help determine whether CD8 
cells are helpful or harmful—an understanding that may one 
day lead to a vaccine or new therapies. 
In collaboration with John Wherry, Professor in the 
Department of Microbiology at Penn’s Perelman School 
of Medicine, Scott found that having a prior viral infection 
before acquiring leishmaniasis can lead to a more aggressive 
form of disease, likely because the immune system’s CD8 
T cells have already been primed to respond to invading 
pathogens.
In addition, a partnership with Elizabeth Grice, Assistant 
Professor in the Department of Dermatology at Penn 
Medicine, has focused on the role of the skin microbiome—
the collected community of bacteria, viruses, parasites, 
and other microbes—in disease progression. In mice, 
they’ve found that leishmaniasis infection transforms the 
microbiome, causing certain types of microbes to become 
dominant that they believe may exacerbate disease. One 
possibility is that using an antibiotic to reduce populations 
of these dominant microbes could supplement and boost the 
effectiveness of standard leishmaniasis therapies.
Scott and his Brazilian colleagues are also embarking 
on a new project that will use blood and tissue samples 
from patients in Brazil to further elucidate the biology of 
the disease. Researchers will obtain genomic sequences 
from parasites, analyze the patients’ skin microbiomes, and 
perform transcriptional analyses on lesion tissue compared 
to normal tissue to see what genes are activated during 
infection.
“With this work, we’ll get a full picture of what’s 
happening in these patients,” Scott says. “One thought is 
that we could define biomarkers for progression to serious 
disease or perhaps even drug targets.”
For now, however, researchers are hoping to leverage 
drugs that are already on the market to make an impact 
against leishmaniasis. First up is an inflammation-blocking 
compound called anakinra, which is widely used to treat 
rheumatoid arthritis. Scott’s lab has shown that anakinra is 
extremely effective against leishmaniasis in mice; now he 
is helping design a clinical trial that will enroll a handful of 
human patients in Brazil. 
“Most tropical diseases don’t get the attention of drug 
companies, so if we can use a drug that is already available 
to effectively treat leishmaniasis, it’s a win-win,” Scott says.
Parasitic diseases have largely been wiped out in humans 
in the developed world. But since they remain a problem 
in companion animals, veterinary schools—including Penn 
Vet—have a strong history in the field of parasitology. Scott 
and his fellow scientists are continuing in this tradition, 
applying the concept of One Health to understand parasite 
biology and, perhaps one day soon, reap important benefits 
for human and animal health around the world.
“Working on this disease provides an opportunity to do 
some really interesting basic science with a great team and, 
what’s even more exciting, to do something that might help 
a lot of people,” Scott says. 
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(At left) The life cycle of leishmaniasis; (At right) The infective stage of 
the Leishmania parasite in the presence of two types of macrophages 
(stained blue and green) that the parasite can infect.  
